You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 18, 2024

AGGRENOX Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Aggrenox patents expire, and when can generic versions of Aggrenox launch?

Aggrenox is a drug marketed by Boehringer Ingelheim and is included in one NDA.

The generic ingredient in AGGRENOX is aspirin; dipyridamole. There are twenty-two drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the aspirin; dipyridamole profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Aggrenox

A generic version of AGGRENOX was approved as aspirin; dipyridamole by BARR on August 14th, 2009.

  Try a Trial

Drug patent expirations by year for AGGRENOX
Drug Prices for AGGRENOX

See drug prices for AGGRENOX

Drug Sales Revenue Trends for AGGRENOX

See drug sales revenues for AGGRENOX

Recent Clinical Trials for AGGRENOX

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Rutgers, The State University of New JerseyPhase 3
Oklahoma Medical Research FoundationN/A
Boehringer IngelheimPhase 1

See all AGGRENOX clinical trials

Paragraph IV (Patent) Challenges for AGGRENOX
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
AGGRENOX Extended-release Capsules aspirin; dipyridamole 25 mg and 200 mg 020884 1 2007-02-01

US Patents and Regulatory Information for AGGRENOX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim AGGRENOX aspirin; dipyridamole CAPSULE, EXTENDED RELEASE;ORAL 020884-001 Nov 22, 1999 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for AGGRENOX

See the table below for patents covering AGGRENOX around the world.

Country Patent Number Title Estimated Expiration
Finland 873492 ⤷  Try a Trial
Ireland 60862 Pharmaceutical compositions containing dipyridamole or mopidamol and o-acetylsalicylic acid or the physiologically acceptable salts thereof, processes for preparing them and their use in treating clot formation ⤷  Try a Trial
Germany 3767408 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for AGGRENOX

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0257344 20/1999 Austria ⤷  Try a Trial PRODUCT NAME: DIPYRIDAMOL IN KOMBINATION MIT ACETYLSALICYLSAEURE; NAT. REGISTRATION NO/DATE: 1-22779 19981112; FIRST REGISTRATION: FR NL 22160 19970709
0257344 SPC/GB98/043 United Kingdom ⤷  Try a Trial PRODUCT NAME: DIPYRIDAMOLE, OPTIONALLY IN THE FORM OF A PHYSIOLOGICALLY ACCEPTABLE SALT, AND O-ACETYLSALICYLIC ACID, OPTIONALLY IN THE FORM OF A PHYSIOLOGICALLY SALT, I.E. ASASANTIN RETARD; REGISTERED: FR NL 22160 19970709; UK 00015/0224 19980512
0257344 C990001 Netherlands ⤷  Try a Trial PRODUCT NAME: DIPYRIDAMOL, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH AAN- VAARDBAAR ZOUT, EN ACETYLSALICYLZUUR, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH AANVAARDBAAR ZOUT,IN EEN GEWICHTSVERHOUDING TUSSEN DIPYRIDAMOL-BESTANDDEEL EN ACETYLSALICYLZUUR-BESTANDDE; NAT. REGISTRATION NO/DATE: RVG 21171 19980713; FIRST REGISTRATION: FR 343 234.9, 560 483.7 19970709
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.